George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
PMSL, you haven't even bothered to look at their products before posting such tripe let alone see who follows them on Twitter
I respectfully disagree.
Covid attacks the lung. the most intertwined organs are the lungs and the heart. Real time analysis of blood flow is required to ensure there are no unforeseen complications with patients, and if they are, can be responded to immediately. When on a ventilator it poses the exact same risk and monitoring as post surgery. When ventilator usage increase as does the monitoring solutions that accompany them.
You'll notice across italian/US/NHS hospitals all patients in ICU are accompanied with Monitors as it is needed. to assist with human error for a start and offers a more granular solution.
Sausage, are you aware how big the monitors actually are?
They've been around for years so I don't think they are under the radar. LIDCO make cardiac output monitors not ventilators. COVID causes respiratory failure which responds well to patients being proned. Due to the constant bedside patient turning the last thing you want is an additional large cardiac monitor present. Cardiac failure can occur in these cases but it's the bulky kit that gets in the way by the bedside that limits the mass uptake here in ITU's
Sure they may sell the extra bit of kit on the back of ITU cases but I doubt this will be a COVID stock that will sell 000's. The monitors just get in the way and there's enough going on in a small bed space with people wearing full PPE in a packed and overcrowded Intensive care to need non essential bits of kit.
Go and use one or look at one and you'll get the issue.
Yep. Seems that way.
I was looking at Deltex Medical but they fell below my criteria. Website is appalling ( i know that shouldn't matter but it follows the narrative that they are not commercially astute)
I think any small cap Hemodynamic company will see huge gains during the next 6 months. ICU increasing capacities worldwide. Lidco seem to be more aware of the landscape and have a focus (buy out) in comparison to DEMG.
And their SAAS offering is bloody good. The way to go which compounds my belief they are a sales led organisation. And a solid US footprint which is about to blow up.
Been on there at least a week.
There you are Sausage, read the link for yourself. Also check #LIDCO on twitter and you will not see a single post from an investor, this is under the radar mate
A message to the healthcare providers we supportaround the world,We know that with the complex and ever-changing COVID-19 outbreak, you are concerned about protecting the health of your patients and your employees. We too recognise our responsibility as a medical device manufacturer to support the medical community. We are prioritising our activities so that you can feel confident in our ability to support you during this situation. Our operations teams have been working additional hours including the weekends to maintain continuity of supply and service. Our customer service teams are able, if it becomes necessary, to work remotely to support your requests. We are also working closely with government agencies and couriers to monitor the situation and make contingency plans to ensure we can deliver products. We have taken steps to ensure that our employees understand and follow preventative measures recommended by local health authorities and the World Health Organization (WHO). We have implemented employee travel restrictions and postponed events. However, our representatives and clinical teams are here for you and want to help you in whatever capacity you need.Finally, thank you for your efforts at this challenging time -You are all heroes to us!The LiDCO Team
http://www.lidco.com/wp-content/uploads/2020/03/COVID-19.pdf
Ok. Just checked level 2. It's dropped because of 2 large sells. One for £10.5K and the other for £9K. There is a smattering of small buys after this but nothing in comparison to the large sales.
It certainly was mate, I have seen this before where there is just a tiny freefloat involved pre news or pre TR1 where an II is loaded up
Just look at some of the names on the list, Credit Suisse Asset Management
Here is the link:
https://www.marketscreener.com/LIDCO-GROUP-PLC-4003523/company/
Shareholders
Name Equities %
Alto Invest SA 24,387,442 9.99%
Ingalls & Snyder LLC 17,125,579 7.01%
Joe Leitch 16,806,183 6.88%
Herald Investment Management Ltd. 16,666,667 6.83%
Paul Brewer 15,884,747 6.51%
Hargreaves Lansdown Stockbrokers Ltd. 14,108,000 5.78%
James Lawrence Ede-Golightly 12,300,000 5.04%
Credit Suisse Asset Management Ltd. 11,829,000 4.84%
Robert Greenshields 8,899,550 3.64%
Terence K. O'Brien 8,251,563 3.38%
I just bought.
Low volume but have been looking for entry point and your reminder on SDR was welcome.
Thanks Kiwi.
Increased sales demand from China in response to COVID-19
LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring company, announces that its Chinese distribution partner, Beijing Gloryway Medical Company, has recently sold a small number of monitors in Wuhan, China as a direct response to the COVID-19 virus outbreak.
A number of LiDCOrapid monitors had already been installed in the city prior to the COVID-19 outbreak. The recent purchase is to provide additional Intensive Care monitoring capabilities in order to treat the most acute cases of the infection. The transaction was able to be arranged without LiDCO or our distributors' staff visiting Wuhan.
sharehunter3, these Covid19 stocks are definately the way forward. This one has hardly any freefloat due to the IIs buying and holding. It has been NT to buy for a while now
of this share ,thanks for posting info on ncyt share board ,
ncyt starting to move back up some today as more people look to be wanting into shares with covid 19 testing kits will do some research here
hoping you do well here and at ncyt as well
Drop on low volume and NT to BUy
Monitors ... surely they have sold a few in these terrible times.
Monitors are used in ICU and they are building ICU’s in public parks! So should be more than fine. Plus they will be needed for recovery as well, more than just one application. They give a full patient read out with great graphics.
Trek
With the surge of Coronavirus, elective surgery in hospitals has been cancelled across the world (except for life threatening conditions).
Will this have an impact here, in particular the results to be published in April and sales projections for the rest of the year?
Hi Trek, saw your tip on ARB and had a look and have now got involved. Cash and no debt is always a big plus.
It’s not a drop google showing down 1.4. I just tried to buy and was quoted 9.6 buy, 8.6 sell on ii. Thought I was going to get a few on the cheap then! Lol!
Trek
Yes really looking forward to it, got a big holding here albeit late to the party but it doesn’t matter as long as it goes up and I think they are teeing up a big release for US and RoW sales. I have been through RNS’s all way to Apr 2014 and can’t see that they have ever raised which is usually the market fear. It’s not their style, they run a tight ship, costs under control, revenues from sales and recurring remote monitoring revenues. Ebit positive and cash on books. Don’t get why it’s not 50p! Yet! DYOR
Trek
And as for US revenues, also see co website, great ppt presentations...
· US revenues up 47% (42% on a constant currency basis) to £0.9m (H1 2018: £0.6m)
· EBITDA loss reduced by 70% to £0.3m (H1 2018: loss £0.9m)
· Strong balance sheet to support growth strategy with cash balances at 31 July 2019 of £1.2m (31 January 2019: £1.7m), and no debt
Cash and NO DEBT, they will obviously have a credit facility for cheap money but with recurring revenues and sales through the roof they shouldn’t need it. With their market leading differentiated products this imo is a little gem!
Trek